JOINTOWN PHARMACEUTICAL GROUP CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.54 CNY | +0.95% |
|
+5.56% | +21.83% |
| Sales 2023 * | 156B 21.49B | Sales 2024 * | 174B 24.01B | Capitalization | 32.52B 4.49B |
|---|---|---|---|---|---|
| Net income 2023 * | 2.41B 333M | Net income 2024 * | 2.81B 388M | EV / Sales 2023 * | 0.25 x |
| Net Debt 2023 * | 7.1B 981M | Net Debt 2024 * | 9.24B 1.28B | EV / Sales 2024 * | 0.24 x |
| P/E ratio 2023 * |
13.8
x | P/E ratio 2024 * |
11.9
x | Employees | 30,141 |
| Yield 2023 * |
3.55% | Yield 2024 * |
3.91% | Free-Float | 40.28% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.95% | ||
| 1 week | +5.56% | ||
| Current month | +5.96% | ||
| 1 month | +3.26% | ||
| 3 months | +20.96% | ||
| 6 months | +12.07% | ||
| Current year | +21.83% |
1 week
8.04
8.62
1 month
7.708.62
Current year
6.528.95
1 year
6.508.95
3 years
5.128.95
5 years
5.129.87
10 years
5.1216.87
| Managers | Title | Age | Since |
|---|---|---|---|
Wei He
CEO | Chief Executive Officer | 38 | 21-09-30 |
Chang Yun Liu
CHM | Chairman | 42 | 17-07-31 |
Ying Zheng Xu
CHM | Chairman | 51 | 14-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gu Liang Tang
BRD | Director/Board Member | 62 | 20-11-04 |
Bao Lin Liu
FOU | Founder | 71 | 99-02-28 |
Zhao Nian Liu
BRD | Director/Board Member | 64 | 08-11-15 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.42% | 2 M€ | -20.87% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 8.54 | +0.95% | 16 338 950 |
| 24-04-18 | 8.46 | -0.70% | 22,462,940 |
| 24-04-17 | 8.52 | +2.16% | 30,529,100 |
| 24-04-16 | 8.34 | -0.12% | 31,025,660 |
| 24-04-15 | 8.35 | +3.73% | 28,793,540 |
End-of-day quote Shanghai S.E., April 18, 2024
More quotes
Jointown Pharmaceutical Group Co., Ltd. is principally engaged in the wholesaling and retailing of pharmaceuticals and medical equipments. The Company is also engaged in the research, development and production of drugs, as well as the provision of relevant value-added services. The Companyâs products mainly include western medicines, proprietary Chinese medicines, Chinese medicine pieces, Chinese herbal medicines, medical equipments, health care products, cosmetics, among others. The Company mainly provides services to direct sales or franchise stores through its retailing businesses.
Sector
Pharmaceuticals
Calendar
2024-04-26
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
8.46
CNY
Average target price
10.18
CNY
Spread / Average Target
+20.39%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +21.83% | 4.45B | |
| +12.69% | 68.18B | |
| +6.27% | 25.78B | |
| +6.34% | 7.99B | |
| -2.79% | 7.88B | |
| -23.97% | 7.62B | |
| -4.23% | 3.89B | |
| -3.51% | 3.82B | |
| +25.02% | 3.69B | |
| +3.28% | 3.24B |
- Stock Market
- Equities
- 600998 Stock
